Table 1.
Baseline characteristics of prostate cancer patients receiving RAP by BMI status
| Normal | Overweight | Mildly obese | Severely obese | P value | |
|---|---|---|---|---|---|
| BMI < 25 | BMI 25–29.9 | BMI 30–34.9 | BMI 35+ | ||
| n = 361 | n = 794 | n = 290 | n = 68 | ||
| Age at surgery (year), mean (std) | 64.6 ± 8.0 | 62.6 ± 7.4 | 62.6 ± 7.3 | 61.1 ± 7.3 | <0.0001 |
| Race, N (%) | |||||
| White | 307 (85.0) | 728 (91.7) | 265 (91.4) | 60 (88.2) | 0.0002 |
| Asian | 39 (10.8) | 37 (4.7) | 13 (4.5) | 2 (2.9) | |
| Black | 10 (2.8) | 24 (3.0) | 12 (4.1) | 6 (8.8) | |
| Other | 5 (1.4) | 5 (0.6) | 0 (0.0) | 0 (0.0) | |
| PSA (ng/mL), median (std) | 5.3 ± 11.0 | 5.4 ± 5.4 | 5.6 ± 6.5 | 5.5 ± 7.9 | 0.12 |
| PSA group, N (%) | |||||
| 0–3.9 | 72 (20.1) | 158 (20.1) | 41 (14.3) | 13 (19.4) | 0.13 |
| 4–10 | 236 (65.9) | 541 (68.9) | 198 (69.2) | 45 (67.2) | |
| >10 | 50 (14.0) | 86 (11.0) | 47 (16.4) | 9 (13.4) | |
| Clinical stage, N (%) | |||||
| T1abc | 300 (83.1) | 666 (84.2) | 249 (85.9) | 59 (86.8) | 0.74 |
| T12/3 | 61 (16.9) | 125 (15.8) | 41 (14.1) | 9 (13.2) | |
| Gleason score, N (%) | |||||
| 2–4 | 1 (0.3) | 1 (0.1) | 0 (0.0) | 0 (0.0) | 0.004 |
| 5–6 | 224 (62.1) | 514 (65.2) | 180 (62.5) | 34 (50.0) | |
| 7 | 112 (31.0) | 228 (28.9) | 90 (31.3) | 20 (29.4) | |
| 8–10 | 24 (6.7) | 46 (5.8) | 18 (6.3) | 14 (20.6) | |
| Gleason score, mean (std) | 6.4 ± 0.7 | 6.4 ± 0.7 | 6.4 ± 0.7 | 6.8 ± 0.9 | 0.002 |
| Risk group, N (%) | |||||
| Low risk | 195 (54.5) | 463 (59.4) | 154 (54.0) | 31 (46.3) | 0.002 |
| Intermediate risk | 125 (34.9) | 250 (32.1) | 107 (37.5) | 20 (29.9) | |
| High risk | 38 (10.6) | 66 (8.5) | 24 (8.4) | 16 (23.9) | |
| Surgeon, N (%) | |||||
| A | 158 (43.8) | 349(44.0) | 106 (36.6) | 27 (39.7) | 0.30 |
| B | 142 (39.3) | 305 (38.4) | 117 (40.3) | 27 (39.7) | |
| C | 46 (12.7) | 94 (11.8) | 41 (14.1) | 9 (13.2) | |
| D | 15 (4.2) | 46 (5.8) | 26 (9.0) | 5 (7.4) | |